The 36th A3P International Congress will take place on October 7, 8 and 9, 2025. As every year, it brings together the entire profession around the major challenges of the pharmaceutical industry.

For this 2025 edition, A3P would like to share with you testimonials that fall within the following 2 themes:

• Process control in sterile production

• Optimization of Quality processes as recommended by ICH Q10

During these three days, you will find, through 15 conferences , testimonies of the transformation of regulatory and environmental challenges into opportunities, examples of capitalizing on compliance in order to confer a competitive advantage to our pharmaceutical industries, while ensuring the availability of medicines throughout the world.

You will participate in interactive workshops ( 20 workshops offered), and discover an exhibition bringing together more than 120 exhibitors .

This event is a major opportunity to exchange and establish contacts with experts from the pharmaceutical industry.

We look forward to seeing even more of you, to share with you these moments of technical and scientific discussions, of exchanges that are always very professional in a friendly atmosphere that marks the signature, year after year, of the event and its reputation.

The A3P Switzerland Congress in March 2025 will delve into the interpretation and application of the new Annex 1 in Switzerland, with a focus on sharing practical insights and experiences from the industry. Since the publication of Annex 1 Manufacture of Sterile Medicinal Products and its implementation on August 23 with PICs PE 009-17, the pharmaceutical and biotechnology sectors have been faced significant changes in process design, aseptic practices and contamination control requirements. This forum will provide a unique opportunity to discuss Swissmedic’s interpretation of these new requirements and to examine the strategies and challenges encountered by industry leaders in their implementation efforts. Participants will gain insight into compliance expectations and innovative approaches to meet the stringent standards now required for the manufacture of sterile and low microbial load medicinal products.

EU GMP Annex 1 / Patient risk management ICH Q9(R1) / Digitalization